Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Anthony L. Cunningham,Thomas C. Heineman,Himal Lal,Olivier Godeaux,Roman Chlibek,Shinn-Jang Hwang,Janet E. McElhaney,Timo Vesikari,Charles Andrews,Won Suk Choi,Meral Esen,Hideyuki Ikematsu,Martina Kovac Choma,Karlis Pauksens,Stéphanie Ravault,Bruno Salaun,Tino F. Schwarz,Jan Smetana,Carline Vanden Abeele,Peter Van den Steen,Ilse Vastiau,Lily Yin Weckx,Myron J. Levin

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

2018

Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01(B) Adjuvant System, was highly efficacious in preventing herpes zoster in th ...

Keywords:

Virology
Pharmaceutical Adjuvants
Immunology
Immune system
Herpes zoster disease
Glycoprotein
Recombinant glycoprotein
Herpes Zoster Vaccine
Georgia republic
Medicine
Virus
Antibody
Clinical trial
Vaccination
Placebo
Immunogenicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations